SGCA
LABP

Steel Grove Capital Advisors’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Steel Grove Capital Advisors’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000
Closed -$2.98K – 209
2023
Q1 		$2.98K Sell
1,000
-8,450
-89% -$31.2K ﹤0.01% 190
2022
Q4 		$47.3K Buy
9,450
+1,000
+12% +$3.83K 0.01% 178
2022
Q3 		$55K Buy
+8,450
New +$73.3K 0.01% 151

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Steel Grove Capital Advisors's LABP Position: Q2 2023 in Review

Steel Grove Capital Advisors sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2023, closing a stake of 1,000 shares — an estimated $2.98K sold.

Steel Grove Capital Advisors first reported a position in LABP in Q3 2022 and held it in 3 quarters. The position peaked at $55K in Q3 2022. 8 funds tracked by Wall St. Rank hold LABP as of Q2 2023.

  • Steel Grove Capital Advisors reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Steel Grove Capital Advisors sold 1,000 Landos Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $2.98K.
  • Steel Grove Capital Advisors first reported a position in Landos Biopharma, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Steel Grove Capital Advisors's Landos Biopharma, Inc. Common Stock position peaked at $55K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2023.

Based on Steel Grove Capital Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.